Rachel Slyker
Associate
Rachel Slyker is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law.
During law school, Rachel interned in the UCSF Industry Contracts Division. Prior to attending law school, she worked at Genentech, where she gained experience in bioprocessing.
Experience
Rachel Slyker is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on technology transactions and corporate law.
During law school, Rachel interned in the UCSF Industry Contracts Division. Prior to attending law school, she worked at Genentech, where she gained experience in bioprocessing.
Education
- J.D., UC Berkeley School of Law, 2021
- M.S., Biotechnology, Johns Hopkins University, 2018
- B.S., Biochemistry and Cell Biology, University of California, San Diego, 2012
Cum Laude
Admissions
- State Bar of California
Credentials
Education
- J.D., UC Berkeley School of Law, 2021
- M.S., Biotechnology, Johns Hopkins University, 2018
- B.S., Biochemistry and Cell Biology, University of California, San Diego, 2012
Cum Laude
Admissions
- State Bar of California
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Circle Pharma on Research Collaboration with Boehringer Ingelheim
On October 9, 2024, Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced a new research collaboration and licensing agreement with a shared objective to create a pioneering cyclin inhibitor. This innovative development could potentially halt the growth of cancer cells in patients living with hard-to-treat cancers. Wilson Sonsini advised Circle on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Apexigen on Acquisition by Pyxis Oncology
On May 24, 2023, Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction. Wilson Sonsini Goodrich & Rosati is advising Apexigen on the transaction.
Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share. Upon the closing of this business combination, Apexigen will become a wholly owned subsidiary of Pyxis Oncology. The definitive merger agreement has been approved by the boards of directors of each company and is anticipated to close by mid-2023, subject to the satisfaction or waiver of customary closing conditions.
Apexigen’s sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has been evaluated in more than 500 patients in clinical trials and demonstrated strong activity, including rapid, deep, and durable responses and a favorable tolerability profile, across multiple difficult-to-treat tumor types. Xiaodong Yang, M.D., Ph.D., CEO of Apexigen, stated, “I am proud of the foundational work Apexigen has done to advance sotigalimab into Phase 2 trials across multiple solid tumor types. Apexigen and Pyxis Oncology share a common vision of bringing innovative solutions to oncology patients. With Pyxis Oncology’s strong cash position and its commitment to further sotigalimab’s development, we believe that this transaction will greatly enhance the opportunity to efficiently advance sotigalimab for patients suffering from a variety of difficult-to-treat cancers. Additionally, coupling our APXiMAB antibody platform with Pyxis Oncology’s complementary ADC technology platform will magnify the therapeutic potential of the APXiMAB platform.”
The Wilson Sonsini team that advised Apexigen on the transaction includes:
Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each share of Apexigen common stock, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share. Upon the closing of this business combination, Apexigen will become a wholly owned subsidiary of Pyxis Oncology. The definitive merger agreement has been approved by the boards of directors of each company and is anticipated to close by mid-2023, subject to the satisfaction or waiver of customary closing conditions.
Apexigen’s sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has been evaluated in more than 500 patients in clinical trials and demonstrated strong activity, including rapid, deep, and durable responses and a favorable tolerability profile, across multiple difficult-to-treat tumor types. Xiaodong Yang, M.D., Ph.D., CEO of Apexigen, stated, “I am proud of the foundational work Apexigen has done to advance sotigalimab into Phase 2 trials across multiple solid tumor types. Apexigen and Pyxis Oncology share a common vision of bringing innovative solutions to oncology patients. With Pyxis Oncology’s strong cash position and its commitment to further sotigalimab’s development, we believe that this transaction will greatly enhance the opportunity to efficiently advance sotigalimab for patients suffering from a variety of difficult-to-treat cancers. Additionally, coupling our APXiMAB antibody platform with Pyxis Oncology’s complementary ADC technology platform will magnify the therapeutic potential of the APXiMAB platform.”
The Wilson Sonsini team that advised Apexigen on the transaction includes:
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.